For US Veterinary Professionals Only

  • For US Veterinary Professionals Only

    BRAVECTO logo

Extraordinary Flea and Tick Protection

THE 12-WEEK* DIFFERENCE IN FLEA AND TICK PROTECTION

The Four Key Differences of Bravecto®

12-WEEKS* OF PROTECTION

Longest-lasting protection available in a single chew or topical dose

FAST ACTING

Kills fleas and ticks within hours of administration1-3,11,16,19

Safe

Proven safe and effective for both dogs and cats for 12 weeks*1-3,7,8,17,18

Enhances Compliance

Decreases chances of pet owner noncompliance compared to monthly products1-4

PRESCRIBE DIFFERENT WEIGHT BANDS OF BRAVECTO DEPENDING ON PET'S WEIGHT1-3

Click the tabs below to view the different products.

Chew for dogs

Topical for dogs

Topical for cats

Bravecto Toy Pet Chewables

4.4-9.9 lb
112.5 MG

Bravecto Small Pet Chewables

>9.9-22.0 lb
250 MG

Bravecto Medium Pet Chewables

>22.0-44.0 lb
500 MG

Bravecto Large Pet Chewables

>44.0-88.0 lb
1,000 MG

Bravecto Extra Large Pet Chewables

>88.0-123.0† lb
1,400MG

†Dogs over 123.0 lb should be administered the appropriate combination of chews.

Indications: Bravecto Chew for Dogs kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

Bravecto Chew for Dogs is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

SEE COMPLETE INFORMATION
Bravecto Topical For Dogs tubes

4.4-9.9 lb
112.5 MG

>9.9-22.0 lb
250 MG

>22.0-44.0 lb
500 MG

>44.0-88.0 lb
1,000 MG

>88.0-123.0† lb
1,400MG

†Dogs over 123.0 lb should be administered the appropriate combination of tubes.

Indications: Bravecto Topical Solution for Dogs kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

Bravecto is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

SEE COMPLETE INFORMATION
Bravecto Topical Cat Packaging

2.6-6.2 lb
112.5 MG

>6.2-13.8 lb
250 MG

>13.8-27.5† lb
500 MG

†Cats over 27.5 lb should be administered the appropriate combination of tubes.

Indications: BRAVECTO Topical Solution for Cats kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of lxodes scapularis (black-legged tick) infestations for up to 12 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pound or greater.

It is also indicated for the treatment and control of Dermacentor variabilis (American dog tick) infestations for 8 weeks in cats and kittens 6 months of age and older weighing 2.6 pounds or greater.

SEE COMPLETE INFORMATION

HEAR HOW VETERINARIANS ARE BREAKING THE FLEA LIFECYCLE WITH BRAVECTO

&npsp;

Dr. Tony Kremer
Illinois

"The most important thing we look for is how do we make things easier for pet parents. And, being able to administer medication to keep them from getting external parasites like fleas and ticks...will make a tremendous difference in how many pets are actually protected."

View MORE TESTIMONIALS submit your BRAVECTO Testimonial
 
 
   
   

I irrevocably grant to Intervet Inc., a subsidiary of Merck & Co., Inc. and its affiliates and their respective officers, directors, employees, agents, successors, licensees and assigns (collectively, "MERCK ANIMAL HEALTH"), the right to take, record, publish or obtain testimonials or other statements from me (collectively, the "Statements") and use, copy, modify, adapt, distribute, publish, display, exhibit and otherwise publish or display in any media, by any means, methods and technologies now known or hereafter to become known, either in whole or in part, the Statements for commercial and business purposes, including, but not limited to, educational, advertising, marketing and promotional materials.

I agree that no advertisement or other material need be submitted to me for any approval. I further waive any and all rights that I may have over the use, distribution, transfer, display, exhibition or other publication of any Statements, including, without limitation, any right to inspect and/or approve such use, publication, distribution, transfer, display, exhibition or other exploitation so long as such Statements are not substantively altered.

I hereby release and discharge, and agree to release and discharge, MERCK ANIMAL HEALTH and its affiliates and their respective officers, directors, employees, agents, successors, licensees and assigns from, and shall neither sue nor bring any proceeding against any such parties for, any claim or cause of action, whether now known or unknown, for defamation, violation of any moral rights, invasion of right of privacy, publicity or personality or any similar matter, or based upon or relating to any use, copying, modification, adaptation, publication, distribution, transfer, display, exhibition or other exploitation of any or all of the Statements.

I further agree that MERCK ANIMAL HEALTH has the right to attribute the Statements (or statements in different words which have substantially the same meaning) to me, which is an expression of my personal experience and belief, including, without limitation, the use of my name and image in connection therewith. I further acknowledge that I am to receive no compensation from MERCK ANIMAL HEALTH relating to the use, copying, modification, adaptation, publication, distribution, transfer, display, exhibition or other exploitation of any or all of the Statements as set forth in this Release or the use of my name and/or image in connection therewith.

Nothing herein will constitute any obligation on MERCK ANIMAL HEALTH to make any use of the Statements or use of any of the rights set forth herein.

I represent and warrant that I am over the age of eighteen (18) years and have read and understand the contents of this Release.  

 
X CLOSE

THE INNOVATIVE DIFFERENCE IN FLEA AND TICK PROTECTION1-3,9 brought to you from Merck Animal Health

Fluralaner molecule

FLURALANER MOLECULE

BRAVECTO (fluralaner) is an isoxazoline, a novel and specific blocker of insect ligand-gated chloride channels. Isoxazoline is the first new insecticide class in more than a decade.1-3,9

However, it is the only isoxazoline that lasts 12 weeks*, decreasing potential gaps in protection.1-3

DISCOVER WHAT MAKES
FLURALANER DIFFERENT1-3,8

&npsp;

View this video to learn how fluralaner works. Fluralaner is now available as a topical solution that works as a selective γ-aminobutyric acid receptor antagonist, binding to chloride channels in nerve and muscle cells of fleas and ticks.2,3

POWERFUL PROTECTION AGAINST A VARIETY OF SPECIES1-3

Chew for dogs

Topical for dogs

Topical for cats

PERSISTENT FLEA CONTROL OVER FULL DOSING PERIOD7,11
Speed of Flea Control

Groups of dogs were flea-infested 2 days prior to treatment and then reinfested with new fleas every 4 weeks. Flea counts on treated and control dogs were conducted at 12 and 24 hours post-treatment and post-infestation. Bravecto’s flea control efficacy was found to be ≥98.7% within 12 hours for 12 weeks.1,7,11

Onset of Flea Kill

Groups of dogs were infested with fleas 1 day prior to treatment. Flea counts were conducted on control and treated groups at 0.5, 1, 2, and 4 hours posttreatment. Bravecto begins killing fleas within 2 hours of administration, with 88% efficacy within 4 hours and 100% efficacy within 12 hours after treatment.1,7,11

Overall Flea Control vs Competitors

Bravecto efficacy was evaluated in a 12-week, multicenter clinical field study. One dose of Bravecto was compared to 3 monthly doses of Spinosad combined with an Amitraz collar. In the same study, clinical signs of FAD were substantially reduced after a single dose.7,12

Consistently more flea-free dogs at week 4 and week 12

Bravecto efficacy was evaluated in a 12-week, multicenter clinical field study. One dose of Bravecto was compared to 3 monthly doses of Spinosad combined with an Amitraz collar.12

FAST AND PERSISTENT FLEA PROTECTION2,8
Speed of Flea Control

Bravecto efficacy was evaluated in a 12-week multicenter, clinical field study.8 Over 12 weeks, there were 3-16x more flea-free dogs with Bravecto than 3 monthly doses of Frontline® Plus.14 And, one dose of Bravecto also reduced fleas by ≥99.8% for 12 weeks.2,20 The study also found that 86%-100% of dogs with signs attributed to flea allergy dermatitis (FAD) had resolution of the following signs by the end of the study:8

- Erythema
- Papules
- Crusts
- Alopecia
- Scales
- Excoriation

Frontline® Plus is a registered trademark of Merial.

AND PERSISTENT FLEA PROTECTION FOR 12 WEEKS3,8
Onset of Flea Kill

Bravecto efficacy was evaluated in a 12-week multicenter, clinical field study.8 Results showed that one dose of Bravecto reduced fleas by >98% within 12 hours for 12 weeks,3,8 and acts quickly, with 100% of fleas killed 8 hours after treatment.3,8 Over 12 weeks of the field study, there were 3-16x more flea-free cats with Bravecto than 3 monthly doses of Frontline® Plus.14,21 The study also found that 80% to 100% of cats with signs attributed to FAD had resolution of the following signs by the end of the study:8

- Erythema
- Papules
- Crusts
- Alopecia
- Scales
- Excoriation

Frontline® Plus is a registered trademark of Merial.

Chew for dogs

Topical for dogs

Topical for cats

TICK CONTROL WITH BRAVECTO16
Tick Control with Bravecto

P<0.0001 vs untreated controls
Data obtained from a European laboratory study determining the speed of kill of Bravecto administered once orally at a dose of 25 mg/kg body weight against tick (Ixodes ricinus) infestations (difference from untreated control dogs, P<0.0001) found that Bravecto’s efficacy of tick control is ≥98.3% within 12 hours for up to 12 weeks.16

Tick efficacy in dogs

Bravecto efficacy was evaluated at 72 hours post-treatment for 12 weeks in a clinical field study. Results found that Bravecto has a ≥93% effectiveness for 12 weeks against Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) and ≥90% effectiveness for 8 weeks against Amblyomma americanum (lone star tick).1 It also found that Bravecto reduces exposure to ticks, which can carry tick-borne diseases.

WITH BRAVECTO, TICKS ON THE DOG ARE KILLED WITHOUT ENGORGEMENT

Bravecto efficacy was tested against a control group. Black-legged ticks (Ixodes scapularis) were removed from dogs in both groups and squeezed to reveal ingested fluid or blood at daily intervals. Ticks from control dogs were alive; ticks from Bravecto-treated dogs were dead. Minimal or no fluid is noted from ticks removed from dogs treated with Bravecto, whereas ticks from control dogs showed engorgement.10

KILLS TICKS FAST

The immediate tick efficacy of Bravecto was evaluated alongside three other commercially available treatments. At 8 hours post-treatment, dogs treated with Bravecto had the lowest number of live ticks attached.19

Bravecto also reached 100% efficacy at 12 hours. In contrast, afoxolaner took a full 48 hours to reach 100% efficacy and imidacloprid + permethrin only reached 80.1% efficacy during the 48-hour study.19

LASTING TICK PROTECTION FOR DOGS2,8
In Dogs

Bravecto efficacy was evaluated in a 12 week clinical field study. Results found that Bravecto has a ≥93.3% effectiveness for 12 weeks against Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) and ≥90% effectiveness for 8 weeks against Amblyomma americanum (lone star tick).2 Bravecto was also shown to reduce exposure to ticks, which can carry tick-borne diseases.

LASTING TICK PROTECTION3,8
In Cats

Bravecto efficacy was evaluated in 12-week clinical field studies. Against black-legged ticks, Bravecto had >94% effectiveness 48 hours post-infestation for 12 weeks, and had >98% effectiveness against American dog ticks 48 hours post-infestation for 8 weeks.3,8

BRAVECTO IS PROVEN SAFE1-3,6,7,16,17

DOGS
Bravecto has been approved for use in breeding, pregnant, and lactating female dogs.1,2 Bravecto is safe to use and efficacious in adult dogs and puppies over 6 months of age and weighing 4.4 lb. or greater.1,2 It has been tested and found safe in puppies 8 to 9 weeks of age at 5x the label dose.1,2,17 No adverse effects with Bravecto Chew for Dogs in MDR-1 gene-deficient collies at 3x the recommended dose.18

CATS
Bravecto is safe to use and efficacious in adult cats and kittens over 6 months of age and weighing 2.6. lb. or greater.3 It has been tested and found safe in kittens 11 to 13 weeks of age at 5x the label dose.3

PROVEN SAFETY
No known contraindications for Bravecto Chew for Dogs and Bravecto Topical Solution for Dogs and Cats.1-3

No problems reported in field trials in dogs and cats that received Bravecto concurrently with other commonly used medication.1-3

Bravecto has not been shown to be effective for 12-weeks' duration in puppies or kittens less than 6 months of age. Bravecto Chew: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. Bravecto Topical Solution for Dogs: The most common adverse reactions recorded in clinical trials were vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Use caution in dogs with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. Bravecto Topical Solution for Cats: The most common adverse reactions recorded in clinical trials were vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. Bravecto is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of Bravecto has not been established in breeding, pregnant and lactating cats. Use with caution in cats with a history of neurologic abnormalities. Neurologic abnormalities have been reported in cats receiving Bravecto, even in cats without a history of neurologic abnormalities.

In field studies and safety studies, no dogs or cats experienced serious adverse events.1-3,7,8

In margin of safety studies, kittens and puppies were dosed at three, 8-week intervals.

CONTACT US ABOUT THE 12-WEEK* DIFFERENCE

Have questions or comments about Bravecto? Contact us today so that we can help you start prescribing Bravecto for the dogs and cats at your clinic.

Contact Us

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.

Bravecto kills fleas and prevents flea infestations. Bravecto Chew and Bravecto Topical Solution for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. Bravecto Topical for Cats kills ticks (black-legged tick) for 12 weeks and American dog ticks for 8 weeks.

IMPORTANT SAFETY INFORMATION:
Bravecto has not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. Bravecto Chew: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. Bravecto Topical Solution for Dogs: The most common adverse reactions recorded in clinical trials were vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Use caution in dogs with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. Bravecto Topical for Cats: The most common adverse reactions recorded in clinical trials were vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. Bravecto is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of Bravecto has not been established in breeding, pregnant and lactating cats. Use with caution in cats with a history of neurologic abnormalities. Neurologic abnormalities have been reported in cats receiving Bravecto, even in cats without a history of neurologic abnormalities.

References: 1. Bravecto Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014. 2. Bravecto Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 3. Bravecto Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 4. Rohdich N, Roepke RKA, Zschiesche E. A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto™ (fluralaner) against Frontline™ (fipronil) in flea- and tick-infested dogs. Parasites & Vectors. 2014; 7:83. 5. Beck S, Schein E, Baldermann C, von Samson-Himmelstjerna G, Kohn B. Tick infestation and tick prophylaxis in dogs in the area of Berlin/Brandenburg – results of a questionnaire study. Berl Munch Tierarztl Wochenschr. 2013;126(1-2):69-76. 6. Kidd L, Breitschwerdt EB. Transmission times and prevention of tick-borne diseases in dogs. Compend Contin Educ Pract Vet. 2003; (25)10:742-751. 7. Freedom of Information Summary, NADA 141-426. Approved May 15, 2014. 8. Freedom of Information Summary, NADA 141-459. Approved 2016. 9. Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014; 45:111-124. 10. Williams H, Demeler J, Taenzler J, Roepke RK, Zshiesche E, Heckeroth AR. A quantitative evaluation of the extent of fluralaner uptake by ticks (Ixodes ricinus, Ixodes scapularis) in fluralaner (Bravecto™) treated vs. untreated dogs using the parameters tick weight and coxal index. Parasites & Vectors. 2015; 8:352. 11. Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (Bravecto™) against Ctenocephalides felis on dogs. Parasites & Vectors. 2014; 7:567. 12. Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling flea infestations. Parasites & Vectors. 2014; 7:375. 13. CAPCvet.org. Accessed July 5, 2016. 14. Data on File, Merck Animal Health. 15. Taenzler J, Liebenberg J, Roepke RKA, Heckeroth AR. Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™). Parasites & Vectors. 2015; 8:305. 16. Wengenmayer C, Williams H, Zschiesche E, et al. The speed of kill of fluralaner (Bravecto™) against lxodes ricinus ticks on dogs. Parasites & Vectors. 2014; 7:525. 17. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasites & Vectors. 2014;7:87. 18. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) collies after oral administration. Parasites & Vectors. 2014;7:86. 19. Burgio et al. Parasites & Vectors (2016) 9:626.

Contact Us